Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

November 21, 2022 Healthcare Heroes Awards 2022

2022 Healthcare Hero: BioXcel Therapeutics Inc.

Winner Category:Corporate Achievement - Innovation Top executive: Founder and Chief Executive Officer Vimal Mehta Return to honoree page
More Information

BioXcel Therapeutics’ mission is to develop transformative medicines utilizing artificial intelligence approaches in neuroscience and immuno-oncology.

What have been the organization’s most significant achievements in the past year?

In 2022, we secured our first Food and Drug Administration approval in an indication that has not seen new innovation in nearly a decade, while also advancing our clinical pipeline.

On April 5, 2022, the FDA approved IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI (developed as BXCL501) is the first and only FDA-approved sublingual film for adults in this indication and addresses a difficult-to-treat neuropsychiatric symptom that represents a significant burden for patients, caregivers and the healthcare system. The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose.

What are some major challenges the organization had to overcome?

Pharmaceutical companies often face the challenge of bringing new therapies to market as quickly as possible. Using our unique AI platform, we progressed from Investigational New Drug (IND) acceptance to IGALMI launch in four years.

What’s the organization’s next major goal?

Moving forward, we will execute our ‘land and expand’ strategy to explore expanding the medical settings, indications, and geographies for our lead neuroscience candidate (BXCL501). We will also leverage our innovative AI ecosystem to further develop our clinical pipeline.

Return to honoree page

Sign up for Enews


Order a PDF